SGLT-2抑制剂治疗糖尿病肾病的研究进展(4)
[13] Sahasrabudhe V,Terra SG,Hickman A,et al. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects with Type 2 Diabetes Mellitus [J]. J Clin Pharmacol,2017,57(11):1432-1443.[14] Seino Y,Yabe D,Sasaki T,et al. SGLT2 inhibitor luseog-liflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes:a 52-week ......
您现在查看是摘要页,全文长 2549 字符。